Stryker (SYK) Q1 2026 Earnings Preview: Guidance and Cyberattack Effects in Focus
Key Takeaways
- Analysts expect Q1 2026 revenue of $6.29 billion, a 7.3% increase from $5.9 billion in the year-ago quarter.
- Consensus adjusted EPS is forecasted at $2.98, up 4.9% year-over-year from $2.84.
- Investors are watching for commentary on the March cyberattack's effects on operations and margins.
- Stryker reaffirmed confidence in its full-year 2026 guidance of 8.0%-9.5% organic net sales growth despite disruptions.
- Key segments like Orthopaedics and Neurotechnology are expected to drive growth amid rising procedure volumes.
- The stock has shown mixed reactions to past earnings, with beats often supporting gains.
Why Stryker's Q1 Earnings Matter Now
Stryker Corporation (SYK), a global leader in medical technologies with specialties in orthopaedics, MedSurg and Neurotechnology, and Spine products, is set to report Q1 2026 results. This comes after a strong 2025, marked by 11.4% full-year organic sales growth. From what I see, investors are keenly focused on whether demand holds for procedures like joint replacements and the Mako robotic system, especially amid economic pressures and the March cyberattack that briefly disrupted manufacturing and orders. In a medtech sector grappling with supply chain challenges and tariff risks, SYK's performance will offer insights into broader resilience. Strong results here could reinforce its premium positioning and innovation strengths.
Earnings Expectations
Wall Street looks for net sales of $6.29 billion for the quarter ended March 31, 2026, up 7.3% on a reported basis and with organic growth slightly below the 10.1% from Q1 2025. Adjusted EPS is seen at $2.98, a 4.9% increase from $2.84 a year earlier, supported by volume gains and operational efficiencies. One thing that stands out is Orthopaedics revenue, which should benefit from greater Mako system adoption, alongside Neurotechnology trends in cranial procedures.
The company has guided for 8.0%-9.5% organic net sales growth in fiscal 2026, and updates on margin impacts from the cyber incident will be crucial. SYK has a track record of beating estimates—Q1 2025 saw revenue exceed forecasts by 3.2% and EPS by 4.0%, with shares rising afterward. This pattern highlights how the market rewards outperformance.
Market Reaction and Investor Sentiment
Heading into earnings, sentiment leans cautiously optimistic, even after the March cyberattack by the Handala group that paused some manufacturing but was contained without a projected material impact on full-year guidance. Shares have held in the $320-$330 range lately, showing underlying strength. Risks include potential guidance cuts or margin squeezes. In my view, SYK tends to deliver beats, with post-earnings moves typically featuring modest gains on surprises—though Q4 2025 dipped despite a beat.
Tools I Rely On: Tickeron's AI Screener
One tool I use regularly in my research is Tickeron’s AI Screener, an AI-powered platform for discovering stocks and ETFs. It lets me filter thousands of names using technical patterns, fundamentals, trends, volatility, and AI signals, with customizable criteria like industry, market cap, indicators, price patterns, and performance metrics. This helps pinpoint trade ideas, trending stocks, breakouts, and opportunities far more efficiently than manual scans. I’ve found it particularly useful for comparing medtech peers like SYK ahead of earnings.
Forward Outlook and What to Watch
After earnings, focus will turn to management's stance on 2026 guidance as cyber recovery progresses. I’m watching organic growth closely, especially in high-margin Orthopaedics, where Mako robotic-arm usage reflects procedure demand.
Key segment updates include MedSurg and Neurotechnology for supply chain steadiness, and Spine amid competition. Margin metrics—gross margins around 64% historically and adjusted operating margins—will show cost management post-disruption. I also checked upcoming factors like tariff effects (about $200M annually), M&A such as the Amplitude Vascular deal, and Q2 seasonality. Broader influences like elective surgery backlogs and reimbursement shifts will play a role. Consistent execution across segments remains essential for momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for SYK turns positive, indicating new upward trend
SYK saw its Momentum Indicator move above the 0 level on June 25, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for SYK just turned positive on June 05, 2026. Looking at past instances where SYK's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
SYK moved above its 50-day moving average on June 24, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SYK crossed bullishly above the 50-day moving average on June 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SYK broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SYK entered a downward trend on May 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.084) is normal, around the industry mean (10.752). P/E Ratio (35.265) is within average values for comparable stocks, (61.526). Projected Growth (PEG Ratio) (1.451) is also within normal values, averaging (3.705). Dividend Yield (0.011) settles around the average of (0.018) among similar stocks. P/S Ratio (4.660) is also within normal values, averaging (23.788).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of reconstructive, medical and surgical, and neurotechnology and spine products
Industry MedicalNursingServices
Advertisement